126 related articles for article (PubMed ID: 15816717)
21. [Pharmacological characteristics and clinical efficacy of bosentan].
Fujimoto K; Ikenoya S
Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):407-18. PubMed ID: 16462092
[No Abstract] [Full Text] [Related]
22. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
[TBL] [Abstract][Full Text] [Related]
23. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension.
Dhillon S; Keating GM
Am J Cardiovasc Drugs; 2009; 9(5):331-50. PubMed ID: 19791841
[TBL] [Abstract][Full Text] [Related]
24. [Dyspnea. When is it pulmonary hypertension?].
MMW Fortschr Med; 2003 Aug; 145(33-34):62. PubMed ID: 14526588
[No Abstract] [Full Text] [Related]
25. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.
Hachulla E; Coghlan JG
Ann Rheum Dis; 2004 Sep; 63(9):1009-14. PubMed ID: 15308510
[TBL] [Abstract][Full Text] [Related]
26. Bosentan.
Bell SG
Neonatal Netw; 2011; 30(4):249-51. PubMed ID: 21729856
[No Abstract] [Full Text] [Related]
27. [Endothelin].
Maeda S; Miyauchi T; Goto K
Nihon Rinsho; 2006 Jul; 64 Suppl 5():112-6. PubMed ID: 16895176
[No Abstract] [Full Text] [Related]
28. [Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study].
Castro G
Rev Port Cardiol; 2001 Nov; 20(11):1151-2. PubMed ID: 11826707
[No Abstract] [Full Text] [Related]
29. Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment.
Dandel M; Lehmkuhl HB; Mulahasanovic S; Weng Y; Kemper D; Grauhan O; Knosalla C; Hetzer R
J Heart Lung Transplant; 2007 Sep; 26(9):898-906. PubMed ID: 17845928
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn.
Mohamed WA; Ismail M
J Perinatol; 2012 Aug; 32(8):608-13. PubMed ID: 22076415
[TBL] [Abstract][Full Text] [Related]
31. Endothelin and endothelin receptor antagonists in systemic rheumatic disease.
Mayes MD
Arthritis Rheum; 2003 May; 48(5):1190-9. PubMed ID: 12746891
[No Abstract] [Full Text] [Related]
32. Macitentan (Opsumit) for pulmonary arterial hypertension.
Med Lett Drugs Ther; 2014 Feb; 56(1436):15-6. PubMed ID: 24663031
[No Abstract] [Full Text] [Related]
33. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation.
Hefke T; Zittermann A; Fuchs U; Schulte-Eistrup S; Gummert JF; Schulz U
Thorac Cardiovasc Surg; 2012 Feb; 60(1):26-34. PubMed ID: 21432755
[TBL] [Abstract][Full Text] [Related]
34. Funding linked to ongoing research: impact of the bosentan patient registry on pricing in Australia.
Wlodarczyk J; Reid CM; Pater G
Value Health; 2011; 14(6):961-3. PubMed ID: 21914519
[TBL] [Abstract][Full Text] [Related]
35. Medication approved to treat rare lung disorder.
FDA Consum; 2002; 36(2):5. PubMed ID: 11989474
[No Abstract] [Full Text] [Related]
36. [2 studies for heart failure therapy. Endothelin receptor antagonist does not improve prognosis].
MMW Fortschr Med; 2002 Apr; 144(14):8. PubMed ID: 12014288
[No Abstract] [Full Text] [Related]
37. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.
Sitbon O; Gressin V; Speich R; Macdonald PS; Opravil M; Cooper DA; Fourme T; Humbert M; Delfraissy JF; Simonneau G
Am J Respir Crit Care Med; 2004 Dec; 170(11):1212-7. PubMed ID: 15317666
[TBL] [Abstract][Full Text] [Related]
38. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
39. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
Nishibu A; Sakai E; Oyama N; Yamamoto T
Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
[TBL] [Abstract][Full Text] [Related]
40. Combined endothelin receptor antagonist and transcatheter interventional therapy of patent ductus arteriosus with severe pulmonary artery hypertension.
Ussia GP; Mulè M; Caruso E; Aiello R; Tamburino C
Int J Cardiol; 2007 Apr; 116(3):427-9. PubMed ID: 16875749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
